Clinical trial
Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced…
NCT00100932 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00100932 |
|---|---|
| Title | Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy |
| Official title | Phase II Study of E7389, a Halichondrin B Analog, in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC), Who Progressed During or After Platinum-Based Doublet Chemotherapy Stratified for Prior Taxane Therapy |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | E7389 28 Day Cycle, E7389 21 Day Cycle |
| Enrollment | 106 |
| Start date | Dec 1, 2004 |
| Primary completion | Jun 1, 2008 |
| First posted | Jan 10, 2005 |
| Last update posted | Mar 27, 2012 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: